Holistic Financial Partners Cuts Position in Pfizer Inc. (NYSE:PFE)

Holistic Financial Partners decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 16.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,992 shares of the biopharmaceutical company’s stock after selling 1,744 shares during the period. Holistic Financial Partners’ holdings in Pfizer were worth $252,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Olistico Wealth LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in Pfizer during the second quarter valued at approximately $29,000. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer in the 2nd quarter valued at $34,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PFE shares. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Price Performance

NYSE:PFE opened at $29.01 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm’s 50-day moving average price is $28.99 and its 200-day moving average price is $28.01. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $36.29.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.